Effects of increasing serum luteinizing hormone levels during early phase of the gonadotropin-releasing hormone antagonist protocol on clinical outcomes of the in vitro fertilization cycle

References

• Lambalk CB, Banga FR, Huirne JA, et al. GnRH antagonist versus long agonist protocols in IVF: a systematic review and meta-analysis accounting for patient type. Hum Reprod Update. 2017;23(5):560–579.
   PubMed Web of Science ®Google Scholar
• Al-Inany HG, Youssef MA, Aboulghar M, et al. Gonadotrophin‐releasing hormone antagonists for assisted reproductive technology. Cochrane Database Syst Rev. 2011;5:CD001750.
   PubMed Web of Science ®Google Scholar
• Alviggi C, Mollo A, Clarizia R, et al. Exploiting LH in ovarian stimulation. Reprod Biomed Online. 2006;12(2):221–233.
   PubMedGoogle Scholar
• Alviggi C, Clarizia R, Mollo A, et al. Who needs LH in ovarian stimulation? Reprod Biomed Online. 2011;22(1):S33–S41.
   PubMedGoogle Scholar
• Marchiani S, Tamburrino L, Benini F, et al. LH supplementation of ovarian stimulation protocols influences follicular fluid steroid composition contributing to the improvement of ovarian response in poor responder women. Sci Rep. 2020;10(1):12907.
   PubMedGoogle Scholar
• Kol S. LH supplementation in ovarian stimulation for IVF: the individual, LH deficient, patient perspective. Gynecol Obstet Invest. 2020;85(4):307–311.
   PubMedGoogle Scholar
• Wang AC, Wang Y, Wu FX, et al. Assessing predictors for the success of GnRH antagonist protocol in reproductive women in IVF/ICSI - in fresh cycles. Biomed Rep. 2017;7(5):482–486.
   PubMedGoogle Scholar
• Xu Y, Zhang YS, Zhu DY, et al. Influence of GnRH antagonist in reproductive women on in vitro fertilization and embryo transfer in fresh cycles. Biomed Rep. 2019;10:113–118.
   PubMedGoogle Scholar
• Barberi M, Ermini B, Morelli MB, et al. Follicular fluid hormonal profile and cumulus cell gene expression in controlled ovarian hyperstimulation with recombinant FSH: effects of recombinant LH administration. J Assist Reprod Genet. 2012;29(12):1381–1391.
   PubMedGoogle Scholar
• Reichman DE, Zakarin L, Chao K, et al. Diminished ovarian reserve is the predominant risk factor for gonadotropin-releasing hormone antagonist failure resulting in breakthrough luteinizing hormone surges in in vitro fertilization cycles. Fertil Steril. 2014;102(1):99–102.
   PubMed Web of Science ®Google Scholar
• Dovey S, McIntyre K, Jacobson D, et al. Is a premature rise in luteinizing hormone in the absence of increased progesterone levels detrimental to pregnancy outcome in GnRH antagonist in vitro fertilization cycles. Fertil Steril. 2011;96(3):585–589.
   PubMedGoogle Scholar
• Luo W, Gumen A, Haughian JM, et al. The role of luteinizing hormone in regulating gene expression during selection of a dominant follicle in cattle. Biol Reprod. 2011;84(2):369–378.
   PubMedGoogle Scholar
• Blockeel C, Sterrenburg MD, Broekmans FJ, et al. Follicular phase endocrine characteristics during ovarian stimulation and GnRH antagonist cotreatment for IVF: RCT comparing recFSH initiated on cycle day 2 or 5. J Clin Endocrinol Metab. 2011;96(4):1122–1128.
   PubMedGoogle Scholar
• Younis JS, Izhaki I, Ben-Ami M. The effect of rLH supplementation to the GnRH-antagonist protocol on endocrine dynamics in the advanced reproductive age. J Endocrinol Invest. 2017;40(8):831–839.
   PubMedGoogle Scholar
• Hershkop E, Segal L, Fainaru O, et al. ‘Model’ versus ‘everyday’ patients: can randomized controlled trial data really be applied to the clinic? Reprod Biomed Online. 2017;34(3):274–279.
   PubMedGoogle Scholar
• Vanetik S, Beck-Fruchter R, Segal L, et al. The importance of mid-follicular phase luteinizing hormone rise in GnRH antagonist-based ovarian stimulation for IVF. Gynecol Obstet Invest. 2020;85(2):184–188.
   PubMedGoogle Scholar
• Fowler PA, Sorsa-Leslie T, Harris W, et al. Ovarian gonadotrophin surge-attenuating factor (GnSAF): where are we after 20 years of research? Reproduction. 2003;126(6):689–699.
   PubMedGoogle Scholar
• Ramachandran A, Jamdade K, Kumar P, et al. Is there a need for luteinizing hormone (LH) estimation in patients undergoing ovarian stimulation with gonadotropin-releasing hormone (GnRH) antagonists and recombinant follicle-stimulating hormone (rFSH)? J Clin Diagn Res. 2014;8:90–92.
   PubMedGoogle Scholar
• Kummer NE, Weitzman VN, Benadiva CA, et al. In vitro fertilization outcomes in patients experiencing a premature rise in luteinizing hormone during a gonadotropin-releasing hormone antagonist cycle. Fertil Steril. 2011;95(8):2592–2594.
   PubMed Web of Science ®Google Scholar
• König TE, van der Houwen LE, Overbeek A, et al. Recombinant LH supplementation to a standard GnRH antagonist protocol in women of 35 years or older undergoing IVF/ICSI: a randomized controlled multicentre study. Hum Reprod. 2013;28(10):2804–2812.
   PubMedGoogle Scholar
• Zhang D, Zhang D, Sun Z, et al. The effect of a transient premature luteinizing hormone surge without elevated serum progesterone on in vitro fertilization outcomes in a gonadotropin-releasing hormone antagonist flexible protocol. Gynecol Endocrinol. 2020;36(6):550–553.
   PubMedGoogle Scholar
• Geng Y, Lai Q, Xun Y, et al. The effect of premature luteinizing hormone increases among high ovarian responders undergoing a gonadotropin-releasing hormone antagonist ovarian stimulation protocol. Int J Gynaecol Obstet. 2018;142(1):97–103.
   PubMedGoogle Scholar
• Martinez F, Barri PN, Coroleu B, et al. Women with poor response to IVF have lowered circulating gonadotrophin surge-attenuating factor (GnSAF) bioactivity during spontaneous and stimulated cycles. Hum Reprod. 2002;17(3):634–640.
   PubMedGoogle Scholar
• Lidor AL, Cohen SB, Seidman DS, et al. Preferred treatment of infertile women older than 37 years of age who demonstrate premature luteinization in the first evaluation cycle. Fertil Steril. 2000;73(2):321–324.
   PubMedGoogle Scholar